search
Back to results

Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain

Primary Purpose

Pain, Acute

Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Fentanyl
Fentanyl and Ketamine
Ketamine
Sponsored by
Mercy Health Ohio
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Acute focused on measuring Moderate, Severe, Pain

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 18 - 65 years old
  • Moderate pain defined as 4-6 out of 10, severe pain defined as ≥ 7 out of 10 as defined by the numeric rating pain scale (NRS)
  • Proficient in reading and understanding English
  • Are deemed by the attending physician to require opioid therapy.

Exclusion Criteria:

  • Inability to give consent,
  • Inability to use the numeric rating scale (NRS) score
  • Long-term use of opioids, history of chronic pain
  • Known substance abuse known as excessive use of a drug such as (e.g. alcohol, narcotics or cocaine)
  • Known hypersensitivity to ketamine or fentanyl
  • Pregnancy
  • Alcohol intoxication
  • Depression
  • Anxiety
  • Chronic obstructive pulmonary disease
  • Asthma
  • Cirrhosis
  • On dialysis
  • Acute ischemic stroke
  • Heart rate (HR) less < 60 bpm or > 120 bpm
  • Systolic blood pressure (SBP) < 90 mmHg or > 180 mmHg
  • Ischemic heart disease
  • Ketamine prior to arrival
  • Trauma patients
  • Sepsis or septic shock
  • Weight > 100 kg.

Sites / Locations

  • St. Elizabeth Boardman Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Experimental

Arm Label

Sub-Dissociative Ketamine alone

Fentanyl alone

Sub-dissociative Ketamine and Fentanyl

Arm Description

0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute

1 mg/kg of Fentanyl IV administered over at least 1 minute

Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute

Outcomes

Primary Outcome Measures

Analgesia of combination fentanyl and SDK as assessed using the pain scale 1-10
Analgesia of combination fentanyl and SDK as assessed using the pain scale 1-10
Analgesia of fentanyl as assessed using the pain scale 1-10
Analgesia of fentanyl as assessed using the pain scale 1-10
Analgesia of ketamine as assessed using the pain scale 1-10
Analgesia of katamine as assessed using the pain scale 1-10

Secondary Outcome Measures

OARRS report
A retrospective review of OARRS report will be performed with each patient.
Opioid sparing response as assessed by number of times additional rescue doses of fentanyl were required
Opioid sparing response as assessed by number of times additional rescue doses of fentanyl were required

Full Information

First Posted
March 12, 2019
Last Updated
September 9, 2020
Sponsor
Mercy Health Ohio
search

1. Study Identification

Unique Protocol Identification Number
NCT03959852
Brief Title
Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain
Official Title
A Combination Study With Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain in the Emergency Department
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Terminated
Why Stopped
Residency completed.
Study Start Date
November 18, 2019 (Actual)
Primary Completion Date
June 5, 2020 (Actual)
Study Completion Date
June 5, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mercy Health Ohio

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
The objective of this study is to evaluate the potential opioid-sparing effect associated with the novel combination of fentanyl and sub-dissociative ketamine in adult patients with moderate to severe pain in the emergency department.
Detailed Description
Pain is a very common complaint in the emergency department (ED). The use of opioids to treat moderate to severe pain has increased over the last decade as well as the number of opioid related deaths. In 1999 to 2016, more than 630,000 people died from a drug overdose. Treatment for acute pain has been assessed in the ED, with review of several different pain medications. Sub-dissociative ketamine (SDK) has become a valuable treatment option for acute pain and in recent years, has been of increased interest due to the growing concerns regarding opioid abuse and opioid shortage in the United States. Sub-dissociative ketamine, an NMDA receptor antagonist, has been studied in dose ranges of 1-4.5 mg/kg for dissociative sedation, as well as dose ranges of 0.1-0.3 mg/kg to treat pain. The onset of action for an IV dose of 2 mg/kg has been studied, with onset usually within 30 seconds after injection and anesthetic effect lasting 5-10 minutes. Common side effects include elevated blood pressure, diplopia or nystagmus, nausea and vomiting. More rare and more severe side effects in dissociative doses include respiratory depression, emergency phenomenon, tonic and clonic movements, and anaphylaxis. However, these were rarely, if ever seen, findings in sub-dissociative doses. Several studies indicate that SDK is a safe and effective alternative to opioids for patients with complaints of moderate to severe pain that provides adequate analgesic effect by itself. In particular, several studies have compared SDK versus morphine, particularly looking at pain in individuals with abdominal pain, flank pain, low back pain or musculoskeletal pain, and acute fractures. SDK has also shown to decrease opioid consumption and the need for rescue analgesia. The studies showed that that there was no difference in average pain scores, but the amount of morphine required was significantly decreased. SDK has proven to be a safe alternative, but the side effects, although short, make it less desirable to use. To the investigator's knowledge, there has never been a study focusing on the use of combination fentanyl and SDK. Fentanyl, an opioid agonist, has been studied in low dose forms of 2 mcg/kg for pain, moderate dose forms of 2-20 mcg/kg for major surgical procedures, and high dose forms of 20-50 mcg/kg for orthopedic and open heart surgeries. Onset of action is almost immediate when given IV, and maximal effect of the drug may take several minutes. The usual duration of action is 30-60 minutes. Common side effects include hypertension, hypotension, dizziness, blurred vision, nausea, vomiting and laryngospasm. Serious side effects included respiratory depression, apnea, rigidity, bradycardia, serotonin syndrome, adrenal insufficiency, and if left untreated could cause cardiac arrest and circulatory depression. There have been several combination studies with SDK, but none regarding fentanyl and ketamine. In one study, combination SDK and reduced dose hydromorphone produced rapid pain relief without significant side effects. Another study indicated that morphine and SDK both provided adequate pain relief alone, but combined morphine and SDK required less morphine administration, had faster onset of relief, and provided sustained reduction in pain intensity for up to 2 hours.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Acute
Keywords
Moderate, Severe, Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
6 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sub-Dissociative Ketamine alone
Arm Type
Active Comparator
Arm Description
0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
Arm Title
Fentanyl alone
Arm Type
Active Comparator
Arm Description
1 mg/kg of Fentanyl IV administered over at least 1 minute
Arm Title
Sub-dissociative Ketamine and Fentanyl
Arm Type
Experimental
Arm Description
Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute
Intervention Type
Drug
Intervention Name(s)
Fentanyl
Other Intervention Name(s)
Fentanyl Citrate
Intervention Description
1 mg/kg of Fentanyl IV administered over at least 1 minute
Intervention Type
Combination Product
Intervention Name(s)
Fentanyl and Ketamine
Intervention Description
Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute.
Intervention Type
Drug
Intervention Name(s)
Ketamine
Other Intervention Name(s)
Ketamine Hydrochloride
Intervention Description
0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
Primary Outcome Measure Information:
Title
Analgesia of combination fentanyl and SDK as assessed using the pain scale 1-10
Description
Analgesia of combination fentanyl and SDK as assessed using the pain scale 1-10
Time Frame
ED encounter (less than 24 hours)
Title
Analgesia of fentanyl as assessed using the pain scale 1-10
Description
Analgesia of fentanyl as assessed using the pain scale 1-10
Time Frame
ED encounter (less than 24 hours)
Title
Analgesia of ketamine as assessed using the pain scale 1-10
Description
Analgesia of katamine as assessed using the pain scale 1-10
Time Frame
ED encounter (less than 24 hours)
Secondary Outcome Measure Information:
Title
OARRS report
Description
A retrospective review of OARRS report will be performed with each patient.
Time Frame
ED encounter (less than 24 hours)
Title
Opioid sparing response as assessed by number of times additional rescue doses of fentanyl were required
Description
Opioid sparing response as assessed by number of times additional rescue doses of fentanyl were required
Time Frame
ED encounter (less than 24 hours)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 18 - 65 years old Moderate pain defined as 4-6 out of 10, severe pain defined as ≥ 7 out of 10 as defined by the numeric rating pain scale (NRS) Proficient in reading and understanding English Are deemed by the attending physician to require opioid therapy. Exclusion Criteria: Inability to give consent, Inability to use the numeric rating scale (NRS) score Long-term use of opioids, history of chronic pain Known substance abuse known as excessive use of a drug such as (e.g. alcohol, narcotics or cocaine) Known hypersensitivity to ketamine or fentanyl Pregnancy Alcohol intoxication Depression Anxiety Chronic obstructive pulmonary disease Asthma Cirrhosis On dialysis Acute ischemic stroke Heart rate (HR) less < 60 bpm or > 120 bpm Systolic blood pressure (SBP) < 90 mmHg or > 180 mmHg Ischemic heart disease Ketamine prior to arrival Trauma patients Sepsis or septic shock Weight > 100 kg.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Gemmel
Organizational Affiliation
Director of Research
Official's Role
Study Director
Facility Information:
Facility Name
St. Elizabeth Boardman Hospital
City
Boardman
State/Province
Ohio
ZIP/Postal Code
44512
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
27844474
Citation
Hebsgaard S, Mannering A, Zwisler ST. Assessment of acute pain in trauma-A retrospective prehospital evaluation. J Opioid Manag. 2016 Sep/Oct;12(5):347-353. doi: 10.5055/jom.2016.0351.
Results Reference
background
PubMed Identifier
27208710
Citation
Motov SM, Nelson LS. Advanced Concepts and Controversies in Emergency Department Pain Management. Anesthesiol Clin. 2016 Jun;34(2):271-85. doi: 10.1016/j.anclin.2016.01.006.
Results Reference
background
PubMed Identifier
29127600
Citation
Todd KH. A Review of Current and Emerging Approaches to Pain Management in the Emergency Department. Pain Ther. 2017 Dec;6(2):193-202. doi: 10.1007/s40122-017-0090-5. Epub 2017 Nov 10.
Results Reference
background
PubMed Identifier
28177167
Citation
Bowers KJ, McAllister KB, Ray M, Heitz C. Ketamine as an Adjunct to Opioids for Acute Pain in the Emergency Department: A Randomized Controlled Trial. Acad Emerg Med. 2017 Jun;24(6):676-685. doi: 10.1111/acem.13172. Epub 2017 Mar 22.
Results Reference
background
PubMed Identifier
27864394
Citation
Duncan C, Riley B. BET 2: Low-dose ketamine for acute pain in the ED. Emerg Med J. 2016 Dec;33(12):892-893. doi: 10.1136/emermed-2016-206440.2.
Results Reference
background
PubMed Identifier
23851034
Citation
Jennings PA, Cameron P, Bernard S, Walker T, Jolley D, Fitzgerald M, Masci K. Long-term pain prevalence and health-related quality of life outcomes for patients enrolled in a ketamine versus morphine for prehospital traumatic pain randomised controlled trial. Emerg Med J. 2014 Oct;31(10):840-3. doi: 10.1136/emermed-2013-202862. Epub 2013 Jul 13.
Results Reference
background
PubMed Identifier
27788221
Citation
Lee EN, Lee JH. The Effects of Low-Dose Ketamine on Acute Pain in an Emergency Setting: A Systematic Review and Meta-Analysis. PLoS One. 2016 Oct 27;11(10):e0165461. doi: 10.1371/journal.pone.0165461. eCollection 2016.
Results Reference
background
PubMed Identifier
25624076
Citation
Miller JP, Schauer SG, Ganem VJ, Bebarta VS. Low-dose ketamine vs morphine for acute pain in the ED: a randomized controlled trial. Am J Emerg Med. 2015 Mar;33(3):402-8. doi: 10.1016/j.ajem.2014.12.058. Epub 2015 Jan 7.
Results Reference
background
PubMed Identifier
25817884
Citation
Motov S, Rockoff B, Cohen V, Pushkar I, Likourezos A, McKay C, Soleyman-Zomalan E, Homel P, Terentiev V, Fromm C. Intravenous Subdissociative-Dose Ketamine Versus Morphine for Analgesia in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2015 Sep;66(3):222-229.e1. doi: 10.1016/j.annemergmed.2015.03.004. Epub 2015 Mar 26.
Results Reference
background
PubMed Identifier
27693070
Citation
Motov S, Rosenbaum S, Vilke GM, Nakajima Y. Is There a Role for Intravenous Subdissociative-Dose Ketamine Administered as an Adjunct to Opioids or as a Single Agent for Acute Pain Management in the Emergency Department? J Emerg Med. 2016 Dec;51(6):752-757. doi: 10.1016/j.jemermed.2016.07.087. Epub 2016 Sep 29.
Results Reference
background
PubMed Identifier
28285863
Citation
Pourmand A, Mazer-Amirshahi M, Royall C, Alhawas R, Shesser R. Low dose ketamine use in the emergency department, a new direction in pain management. Am J Emerg Med. 2017 Jun;35(6):918-921. doi: 10.1016/j.ajem.2017.03.005. Epub 2017 Mar 2.
Results Reference
background
PubMed Identifier
25716117
Citation
Sin B, Ternas T, Motov SM. The use of subdissociative-dose ketamine for acute pain in the emergency department. Acad Emerg Med. 2015 Mar;22(3):251-7. doi: 10.1111/acem.12604. Epub 2015 Feb 25.
Results Reference
background
PubMed Identifier
28821365
Citation
Abbasi S, Bidi N, Mahshidfar B, Hafezimoghadam P, Rezai M, Mofidi M, Farsi D. Can low-dose of ketamine reduce the need for morphine in renal colic? A double-blind randomized clinical trial. Am J Emerg Med. 2018 Mar;36(3):376-379. doi: 10.1016/j.ajem.2017.08.026. Epub 2017 Aug 14.
Results Reference
background
PubMed Identifier
25643741
Citation
Ahern TL, Herring AA, Miller S, Frazee BW. Low-Dose Ketamine Infusion for Emergency Department Patients with Severe Pain. Pain Med. 2015 Jul;16(7):1402-9. doi: 10.1111/pme.12705. Epub 2015 Feb 3.
Results Reference
background
PubMed Identifier
9061093
Citation
Dickenson AH. NMDA receptor antagonists: interactions with opioids. Acta Anaesthesiol Scand. 1997 Jan;41(1 Pt 2):112-5. doi: 10.1111/j.1399-6576.1997.tb04624.x.
Results Reference
background
PubMed Identifier
17499654
Citation
Galinski M, Dolveck F, Combes X, Limoges V, Smail N, Pommier V, Templier F, Catineau J, Lapostolle F, Adnet F. Management of severe acute pain in emergency settings: ketamine reduces morphine consumption. Am J Emerg Med. 2007 May;25(4):385-90. doi: 10.1016/j.ajem.2006.11.016.
Results Reference
background
PubMed Identifier
25297798
Citation
Lilius TO, Jokinen V, Neuvonen MS, Niemi M, Kalso EA, Rauhala PV. Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat. Br J Pharmacol. 2015 Jun;172(11):2799-813. doi: 10.1111/bph.12974.
Results Reference
background
PubMed Identifier
9463786
Citation
Wiesenfeld-Hallin Z. Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes? Drugs. 1998 Jan;55(1):1-4. doi: 10.2165/00003495-199855010-00001.
Results Reference
background
PubMed Identifier
23602757
Citation
Ahern TL, Herring AA, Stone MB, Frazee BW. Effective analgesia with low-dose ketamine and reduced dose hydromorphone in ED patients with severe pain. Am J Emerg Med. 2013 May;31(5):847-51. doi: 10.1016/j.ajem.2013.02.008. Epub 2013 Apr 18.
Results Reference
background
PubMed Identifier
25197290
Citation
Ahmadi O, Isfahani MN, Feizi A. Comparing low-dose intravenous ketamine-midazolam with intravenous morphine with respect to pain control in patients with closed limb fracture. J Res Med Sci. 2014 Jun;19(6):502-8.
Results Reference
background
PubMed Identifier
25377395
Citation
Beaudoin FL, Lin C, Guan W, Merchant RC. Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial. Acad Emerg Med. 2014 Nov;21(11):1193-202. doi: 10.1111/acem.12510.
Results Reference
background
PubMed Identifier
12098616
Citation
Bossard AE, Guirimand F, Fletcher D, Gaude-Joindreau V, Chauvin M, Bouhassira D. Interaction of a combination of morphine and ketamine on the nociceptive flexion reflex in human volunteers. Pain. 2002 Jul;98(1-2):47-57. doi: 10.1016/s0304-3959(01)00472-9.
Results Reference
background
PubMed Identifier
22243959
Citation
Jennings PA, Cameron P, Bernard S, Walker T, Jolley D, Fitzgerald M, Masci K. Morphine and ketamine is superior to morphine alone for out-of-hospital trauma analgesia: a randomized controlled trial. Ann Emerg Med. 2012 Jun;59(6):497-503. doi: 10.1016/j.annemergmed.2011.11.012. Epub 2012 Jan 13.
Results Reference
background
PubMed Identifier
19943920
Citation
Johansson P, Kongstad P, Johansson A. The effect of combined treatment with morphine sulphate and low-dose ketamine in a prehospital setting. Scand J Trauma Resusc Emerg Med. 2009 Nov 27;17:61. doi: 10.1186/1757-7241-17-61.
Results Reference
background
Links:
URL
https://www.cdc.gov/drugoverdose/epidemic/index.html
Description
(WONDER), W.-r. o. (2017, August 30). Centers for Disease Control and Prevention. Retrieved August 18, 2018, from CDC.gov: https://www.cdc.gov/drugoverdose/epidemic/index.html
URL
https://www.accessdata.fda.gov/scripts/drugshortages/
Description
U.S. Department of Health and Human Services. (2018, October 15). U.S. Food and Drug Administration. Retrieved October 15, 2018, from https://www.accessdata.fda.gov/scripts/drugshortages/

Learn more about this trial

Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain

We'll reach out to this number within 24 hrs